Canada Markets open in 4 hrs 44 mins

Statera Biopharma, Inc. (STAB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2741-0.0014 (-0.51%)
At close: 04:00PM EDT
0.2750 +0.00 (+0.26%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2850
Open0.2804
Bid0.0000 x 1300
Ask0.0000 x 3100
Day's Range0.2703 - 0.2972
52 Week Range0.2000 - 6.1300
Volume749,301
Avg. Volume7,788,105
Market Cap8.797M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7620
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

    FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company’s independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders’

  • GlobeNewswire

    Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

    FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 18, 2022 indicating that, because the Company was delinquent in filing its quarterly report on Form 10-Q on May 15, 2022 for the first qua

  • GlobeNewswire

    Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

    Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disordersFORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. (“Lay Sciences”), a d